Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RPRX

Royalty Pharma plc

Nov 14 • 03:39PM ET

39.28

-0.45 -1.13 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VFLO VXF IWR VYM SCHM VHT IWD IHE DGRO FNDA

Scroll to Statements

Index	-	P/E	22.46	EPS (ttm)	1.75	Insider Own	21.19%	Shs Outstand	429.03M	Perf Week	1.87%
Market Cap	22.68B	Forward P/E	8.21	EPS next Y	4.78	Insider Trans	-0.03%	Shs Float	336.69M	Perf Month	8.09%
Enterprise Value	33.89B	PEG	2.50	EPS next Q	1.27	Inst Own	76.00%	Short Float	4.22%	Perf Quarter	9.35%
Income	764.74M	P/S	9.65	EPS this Y	10.49%	Inst Trans	-4.03%	Short Ratio	3.45	Perf Half Y	15.46%
Sales	2.35B	P/B	2.63	EPS next Y	4.88%	ROA	4.09%	Short Interest	14.19M	Perf YTD	53.98%
Book/sh	14.95	P/C	23.74	EPS next 5Y	9.00%	ROE	11.51%	52W High	41.24 -4.75%	Perf Year	51.08%
Cash/sh	1.65	P/FCF	9.04	EPS past 3/5Y	8.57% -21.51%	ROIC	5.10%	52W Low	24.05 63.33%	Perf 3Y	-8.71%
Dividend Est.	0.93 (2.36%)	EV/EBITDA	22.10	Sales past 3/5Y	-0.38% 4.52%	Gross Margin	-	Volatility	2.69% 2.91%	Perf 5Y	-4.12%
Dividend TTM	0.88 (2.24%)	EV/Sales	14.42	EPS Y/Y TTM	-31.46%	Oper. Margin	65.19%	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	Nov 14, 2025	Quick Ratio	3.48	Sales Y/Y TTM	3.72%	Profit Margin	32.54%	RSI (14)	59.42	Recom	1.40
Dividend Gr. 3/5Y	7.30% -	Current Ratio	3.48	EPS Q/Q	-45.18%	SMA20	3.25%	Beta	0.45	Target Price	46.43
Payout	43.94%	Debt/Eq	1.40	Sales Q/Q	7.90%	SMA50	6.79%	Rel Volume	0.45	Prev Close	39.73
Employees	99	LT Debt/Eq	1.34	Earnings	Nov 05 BMO	SMA200	13.15%	Avg Volume	4.12M	Price	39.28
IPO	Jun 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.08% 13.47%	Trades		Volume	1,763,201	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Today 12:56PM	Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
Nov-12-25 11:03PM	Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Loading…
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	Loading…
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)
Sep-19-25 04:25PM	Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum (GlobeNewswire)
Sep-17-25 02:27PM	TD Cowen Maintains a Buy on Royalty Pharma (RPRX) (Insider Monkey)
12:43AM	1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore (StockStory)
Sep-16-25 09:28AM	Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts (Insider Monkey)
Sep-11-25 11:13AM	Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program (Insider Monkey)
07:00AM	Loading…
07:00AM	Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation (GlobeNewswire)
Sep-10-25 07:30AM	Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market (GlobeNewswire)
Sep-04-25 04:15PM	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Sep-02-25 08:30PM	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire)
07:15AM	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire)
Aug-29-25 02:57PM	Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase (Insider Monkey)
05:05AM	Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal (Insider Monkey)
04:54AM	Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines (Insider Monkey)
Aug-25-25 01:19PM	BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up (Benzinga)
08:29AM	Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales (BioPharma Dive)
06:33AM	Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters)
06:10AM	Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million (GlobeNewswire)
06:00AM	BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million (Business Wire)
Aug-13-25 04:15PM	Henry Fernandez Steps Down from Royalty Pharma's Board of Directors (GlobeNewswire)
01:35AM	5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call (StockStory)
Aug-12-25 09:10AM	Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT (Insider Monkey)
03:18AM	RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments (StockStory)
Aug-10-25 11:31PM	Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) (StockStory)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings (Zacks)
08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
08:08AM	Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates (StockStory)
07:22AM	Royalty Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:15AM	Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Aug-04-25 11:21PM	Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow (StockStory)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Watch RPRX and 1 to Stay Cautious (StockStory)
Jul-18-25 08:15AM	Royalty Pharma Declares Third Quarter 2025 Dividend (GlobeNewswire)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors (GlobeNewswire)
Jul-16-25 04:15PM	Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
Jun-27-25 08:33AM	5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call (StockStory)
Jun-24-25 07:05AM	Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion (GlobeNewswire)
Jun-18-25 11:39PM	Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks (StockStory)
Jun-12-25 07:26PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Jun-09-25 09:54AM	RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives (StockStory)
Jun-04-25 04:15PM	Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-16-25 04:30PM	Royalty Pharma Completes the Acquisition of Its External Manager (GlobeNewswire)
May-13-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-12-25 04:15PM	Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition (GlobeNewswire)
May-08-25 08:03PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
10:30AM	Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:15AM	Royalty Pharma Reports First Quarter 2025 Results (GlobeNewswire)
May-07-25 12:34PM	Royalty Pharma Q1 2025 Earnings Preview (Seeking Alpha)
May-05-25 09:15AM	Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics (Zacks)
May-01-25 10:01AM	Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-28-25 06:50PM	Alerus (ALRS) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-24-25 08:16AM	Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement (Insider Monkey)
07:36AM	Thomas: Fragile is the word we agreed on (CNBC TV)
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha)
11:20AM	Patient Capital Management Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 04:15PM	Royalty Pharma Declares Second Quarter 2025 Dividend (GlobeNewswire)
Apr-17-25 04:15PM	Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-10-25 06:20AM	Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? (Zacks)
Apr-08-25 04:15PM	Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors (GlobeNewswire)
Apr-02-25 09:47AM	Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Apr-01-25 10:00AM	Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
06:20AM	Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? (Zacks)
Mar-29-25 07:15AM	4 Healthcare Stocks With Massive Gains-and More to Come (MarketBeat)
Mar-27-25 08:15AM	Royalty Pharma Announces Upcoming Investor Day (GlobeNewswire)
Mar-26-25 11:43AM	3 Reasons to Sell RPRX and 1 Stock to Buy Instead (StockStory) -6.52%
Mar-25-25 09:19PM	Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility? (Insider Monkey)
Mar-21-25 11:30AM	Why Is Blue Owl Capital Corporation (OBDC) Down 3% Since Last Earnings Report? (Zacks)
05:12AM	Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks (StockStory)
Feb-27-25 04:15PM	Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-23-25 03:03PM	Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 07:57PM	Analyst Report: Royalty Pharma plc (Morningstar Research)

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norden Gregory	Director	Aug 11 '25	Sale	36.23	33,500	1,213,749	194,848	Aug 11 04:35 PM
Norden Gregory	Director	Aug 11 '25	Proposed Sale	36.23	33,500	1,213,747		Aug 11 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience